Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
KURA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.98 - $24.17
Previous CloseN/A
Volume631.17K
Average Volume (3M)1.73M
Market Cap
$633.77M
Enterprise Value$1.26B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Feb 26, 2025EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding77,763,750
10 Day Avg. Volume1,080,128
30 Day Avg. Volume1,728,337
Standard Deviation0.18
R-Squared0.05
Alpha-0.00154
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.48K
Enterprise Value/Ebitda-6.27
Forecast
1Y Price Target
$27.75Price Target Upside236.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
Market PositionThe company's edge on safety and tolerability for ziftomenib could potentially reduce the first-to-market advantage of a competing product.
Regulatory ProgressThe KOMET-001 registrational study has successfully met its primary endpoint of complete response (CR)/complete response with partial hematologic recovery (CRh).
Strategic CollaborationsKura announced a global strategic collaboration with Kyowa Kirin to develop and commercialize ziftomenib in acute leukemias, with Kura entitled to a $330 million upfront payment and up to $420 million near-term milestone payments.
Bears Say
Competitive ConcernsLack of CR/CRh data disclosure renews questions about zifto's competitive profile, particularly after Kura's unexpected licensing deal with Kyowa Kirin.
Data TransparencyThe lack of disclosure of the CR/CRh rate for KOMET-001 disappointed the market, raising questions about zifto's competitive profile.
Market ReactionAfter the event, Kura’s shares were down 9% aftermarket, which is attributed to the lack of data/numbers.
---
Ownership Overview
1.47% Insiders
11.16% Mutual Funds
1.52% Other Institutional Investors
71.98% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $6.98 and its highest was $24.17 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $633.77M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Feb 26, 2025 which is in 3 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Nov 07, 2024. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.626 by -$0.004.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.64.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 77,763,750 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.626. Following the earnings report the stock price went down -0.506%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
---
Kura Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.75 (236.36% Upside)
$27.75 (236.36% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 845.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $179.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.72%
12-Months-Change
Fundamentals
Return on Equity
-46.28%
Trailing 12-Months
Asset Growth
1.07%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
---
KURA Company Deck
---
KURA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials for ziftomenib, financial stability, and regulatory achievements, but also noted increased expenses and some clinical challenges.Read More>---
KURA Stock 12 Month Forecast
Average Price Target
$27.75
▲(236.36% Upside)
Technical Analysis
Best Analysts Covering KURA
1 Year
1 Year Success Rate
17/43 ratings generated profit
1 Year Average Return
+18.20%
reiterated a buy rating 2 months ago
Copying Leah R. Cann's trades and holding each position for 1 Year would result in 39.53% of your transactions generating a profit, with an average return of +18.20% per trade.
---